Endocrine clinical pharmacist Diana Isaacs, PharmD, explains how both work
In a 4-week pilot trial, verbal fluency scores increased in the group treated with intranasal insulin and scores decreased in the placebo group, but there were no significant paired comparisons identified, reflecting the limited sample size
What insurance companies look for: Common prior authorization criteria include documented BMI meeting the FDA-approved threshold, documentation of weight-related comorbidities (for patients with BMI 27 to 29.9), evidence of previous weight loss attempts (diet, exercise, behavioral modification), a letter of medical necessity from your provider, and sometimes documentation that you have tried and failed other weight loss medications first (step therapy)
Benefits for People With Type 2 Diabetes People with type 2 diabetes saw two noticeable improvements: Lower blood sugar levels , including meaningful HbA1c reductions Steady weight loss , though typically a little less than non-diabetic participants a pattern also seen with injected GLP-1 receptor agonists The blood sugar improvements reflect how GLP-1 receptor agonists support insulin activity and slow digestion, which may help stabilise glucose throughout the day
Moreover, continuous pharmaceutical innovations in diabetes careincluding digital health integrations and personalized medicineare revolutionizing patient management
Personal history of diabetes as important as family history of colorectal cancer for risk of colorectal cancer: a nationwide cohort study
